Xilio Therapeutics Inc [NASDAQ: XLO] stock went on an upward path that rose over 38.38% on Wednesday, amounting to a one-week price increase of more than 59.30%.
Over the last 12 months, XLO stock dropped by -34.76%. The one-year Xilio Therapeutics Inc stock forecast points to a potential upside of 75.09. The average equity rating for XLO stock is currently 1.33, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $60.21 million, with 27.61 million shares outstanding and 19.83 million shares in the current float. Compared to the average trading volume of 154.43K shares, XLO stock reached a trading volume of 3460794 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Xilio Therapeutics Inc [XLO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for XLO shares is $5.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on XLO stock is a recommendation set at 1.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Chardan Capital Markets have made an estimate for Xilio Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 21, 2022. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on January 10, 2022, representing the official price target for Xilio Therapeutics Inc stock. Previously, the target price had yet another raise to $31, while Raymond James analysts kept a Outperform rating on XLO stock.
The Average True Range (ATR) for Xilio Therapeutics Inc is set at 0.12, with the Price to Sales ratio for XLO stock in the period of the last 12 months amounting to 25.51. The Price to Book ratio for the last quarter was 1.80, with the Price to Cash per share for the same quarter was set at 1.71.
XLO Stock Performance Analysis:
Xilio Therapeutics Inc [XLO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 59.30. With this latest performance, XLO shares gained by 82.67% in over the last four-week period, additionally plugging by 26.85% over the last 6 months – not to mention a drop of -34.76% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for XLO stock in for the last two-week period is set at 78.31, with the RSI for the last a single of trading hit 82.81, and the three-weeks RSI is set at 73.88 for Xilio Therapeutics Inc [XLO]. The present Moving Average for the last 50 days of trading for this stock 0.8305, while it was recorded at 1.0532 for the last single week of trading, and 0.8985 for the last 200 days.
Insight into Xilio Therapeutics Inc Fundamentals:
Xilio Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.02 and a Current Ratio set at 2.02.
Xilio Therapeutics Inc [XLO] Institutonal Ownership Details
There are presently around $30.22%, or 51.17%% of XLO stock, in the hands of institutional investors. The top three institutional holders of XLO stocks are: BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC with ownership of 3.79 million shares, which is approximately 13.5618%. ROCK SPRINGS CAPITAL MANAGEMENT LP, holding 3.0 million shares of the stock with an approximate value of $$2.85 million in XLO stocks shares; and ROCK SPRINGS CAPITAL MANAGEMENT LP, currently with $$1.37 million in XLO stock with ownership which is approximately 5.1641%.
